Sanofi backs guidance as it reports higher sales

The French pharma company confirmed that it expects 2023 business earnings per share--a key metric--to grow low-single digit at constant exchange rates, barring unforeseen major adverse events.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.